EICHORPublic-registry site landscape for NCT03740529, “A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL”, a Chronic Lymphocytic Leukemia study sponsored by Loxo Oncology, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03740529 (registry record) |
| Study title | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL |
| Official title | A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) |
| Sponsor | Loxo Oncology, Inc. |
| Condition(s) | Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lymphoma |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 56 |
| Site countries | United States, Australia, France, Italy, Japan, Poland, South Korea, Sweden, Switzerland, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT03740529.
Eichor generates a preliminary site-risk snapshot for NCT03740529 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Chronic Lymphocytic Leukemia trials
← Eichor home · All tracked trials · Chronic Lymphocytic Leukemia studies · Weekly briefs
